sergolexole has been researched along with amesergide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baez, M; Johnson, MP; Loncharich, RJ; Nelson, DL | 1 |
| Cohen, ML; Mann, JJ; McBride, PA; Nimchinsky, E | 1 |
2 other study(ies) available for sergolexole and amesergide
| Article | Year |
|---|---|
Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines.
Topics: Amphetamines; Animals; Binding, Competitive; Cloning, Molecular; Ergolines; Humans; Hydrogen Bonding; Hydrolysis; Inositol Phosphates; Ketanserin; Mutation; Rats; Receptors, Serotonin; Species Specificity; Structure-Activity Relationship; Tryptamines | 1994 |
Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
Topics: Adult; Ergolines; Female; Humans; Ketanserin; Lysergic Acid; Male; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Serotonin; Ritanserin; Serotonin; Serotonin Antagonists | 1990 |